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http://www.biomedcentral.com/1471-2393/12/71RESEARCH ARTICLE Open AccessHealth care costs associated with gestational
diabetes mellitus among high-risk
women – results from a randomised trial
Päivi Kolu1*, Jani Raitanen1,2, Pekka Rissanen2 and Riitta Luoto1Abstract
Background: The costs of gestational diabetes mellitus (GDM) screening have been frequently reported, but total
GDM-related health care costs compared to the health care costs of women without GDM have not been reported.
The aim of this study was to analyse GDM-related health care costs among women with an elevated risk of GDM.
Methods: The study was based on a cluster-randomised GDM prevention trial (N = 848) carried out at maternity
clinics, combined with data from the Finnish Medical Birth Register and Care Registers for Social Welfare and Health
Care. Costs of outpatient visits to primary and secondary care, cost of inpatient hospital care before and after
delivery, the use of insulin, delivery costs and babies’ stay in the neonatal intensive care unit were analysed. Women
who developed GDM were compared to those who were not diagnosed with GDM.
Results: Total mean health care costs adjusted for age, body mass index and education were 25.1% higher among
women diagnosed with GDM (€6,432 vs. €5,143, p < 0.001) than among women without GDM. The cost of inpatient
visits was 44% higher and neonatal intensive care unit use was 49% higher in the GDM group than among women
without GDM. The delivery costs were the largest single component in both groups.
Conclusions: A confirmed GDM diagnosis was associated with a significant increase in total health care costs.
Effective lifestyle counselling by primary health care providers may offer a means of reducing the high costs of
secondary care.
Keywords: Cost, Gestational diabetes mellitus, Primary health careBackground
Gestational diabetes mellitus (GDM) is a term for dia-
betes first appearing during pregnancy and diagnosed
with a glucose tolerance test [1]. The risk of GDM is
associated with low physical activity, being overweight,
and GDM in an earlier pregnancy [2-5]. In Finland the
prevalence of GDM was 10.3–11.2% according to the
Medical Birth Register for the period 2004–2006 [6].
GDM is a growing public health concern [7] and is asso-
ciated with increased overall health care costs [8].
According to earlier research, women with GDM had
18% higher delivery stay costs than women without
GDM [9]. In addition, antenatal outpatient costs due to* Correspondence: paivi.kolu@uta.fi
1UKK Institute for Health Promotion Research, Kaupinpuistonkatu 1, FI-33501,
Tampere, Finland
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reproduction in any medium, provided the orvisits to primary and secondary care were 25% higher
among women with GDM than among women without
a GDM diagnosis [10]. However, overweight (BMI ≥ 25)
as a risk factor for GDM was associated with increased
inpatient and outpatient visits during pregnancy [11,12].
GDM increases the postnatal health care burden due
to an increased risk of neonatal complications, such as
shoulder dystocia [13], foetal malformations [14] and,
type 2 diabetes later in life [15,16]. There is an increas-
ing trend in the incidence of GDM [7,17], which will
consume more health care resources in the future. Thus
cost analysis is a method of measuring the use of
resources and describing the allocation of costs within
the health care sector, and may help to create more
cost-effective treatment procedures. To the best of our
knowledge, there are no reports on the GDM risk group
comparing the pre- and postnatal health care costs ford. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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diagnosis, but there are several studies related to the
costs of screening [18-20]. We have previously reported
the outcomes of GDM prevention in a cluster-
randomised trial [21,22]. The aim of the original trial
was to assess whether the occurrence of GDM can be
prevented by dietary and physical activity counselling.
As a result of the GDM prevention trial lower neonatal
birthweight was seen in the intervention group com-
pared to the group offered usual care, a favourable
change in the consumption of fatty acids and saccharose
intake in the intervention group. In addition, in the
intervention group there was a smaller decrease in MET
minutes per week for at least moderate intensity activity
[22]. The aim of the present study was to describe
GDM-associated health care costs between women with
and without at least one GDM risk factor.
Methods
This cost analysis was based on data from a cluster-
randomised GDM prevention trial (N = 848), conducted
at maternity clinics in Finland in the period from 2007
to 2009. During pregnant women’s routine visits to the
maternity clinic, public health nurses recruited all
women up to 12 weeks pregnant. The inclusion criteria
of the original study were: BMI ≥ 25 kg/m², previous oc-
currence of GDM, or any signs of glucose intolerance, a
macrosomic newborn (≥ 4500 g) in any earlier preg-
nancy, type 1 or 2 diabetes in first- or second-degree
relatives or age ≥ 40 years. Women included in the trial
were either primigravida or multigravida with singleton
pregnancies. The exclusion criteria were: pathological
value in baseline oral glucose tolerance test (OGTT) at
8–12 weeks’ gestation (blood glucose > 5.3 mmol/l at
fasting, > 10.0 mmol/l at 1-hour or >8.6 mmol/l at 2-
hour), type 1 or 2 diabetes before pregnancy, inadequate
Finnish language proficiency, age < 18 years, twin preg-
nancy or physical limitation preventing physical activity.
In the present study, the case definition of GDM
included women with a pathologic oral glucose tolerance
test or ongoing insulin treatment. Women exhibiting no
GDM diagnostic criteria formed a comparison group.
The cost comparison included health care costs accruing
to the municipality of residence and to the patient. The
costs were evaluated from a societal perspective, includ-
ing costs to the patient. This is because, in the tax-based
health care system in Finland, the patients’ municipality
of residence reimburses the real health care costs to the
relevant hospital district. However, the daily charges for
outpatient- and inpatient care also create a small cost to
the patient. The cost analysis included all eligible women
from the GDM prevention trial who had signed a study-
participant consent form and had given us their permis-
sion to use their data in the Medical Birth Register andthe Care Registers for Social Welfare and Health Care.
Because the travel expenses and time costs related to the
use of health services were assumed to be minor, they
were not included in the calculation.
Costs were taken into account from the beginning of
the pregnancy until the last day that the mother and her
newborn spent in hospital after the birth. Information
concerning medication and the number of visits to pri-
mary and secondary care was obtained from maternity
cards filled in by the public health nurse at the maternity
clinic. Information on visits to a diabetes nurse or a diet-
ician was collected from questionnaires filled in by the
mothers at the beginning of the study (at 8–13 gesta-
tional weeks) and again at 26–28 and at 37–39 gesta-
tional weeks. The information on the number of the
mother’s inpatient hospital days before and after the
standard delivery stay, the mode of delivery, the ICD-10
diagnosis code of the mother and newborn and the
number of hospital days of the newborn were obtained
from the Medical Birth Register and the Care Register.
Primary health care costs were based on the average
national unit costs for health care, which includes visits
to the public health nurse and to the doctor [23]. The
costs of visits to secondary care, visits to a diabetes
nurse and a dietician, the modes of delivery, inpatient
days and neonatal intensive care units use were esti-
mated by using the unit costs of the Tampere University
Hospital, which was the hospital in which 93% of the de-
liveries took place and is the second largest hospital in
Finland [24]. The unit costs were entered at the price
level for 2009. Unit costs of obstetric outpatient and in-
patient care included salary costs and administrative
expenses, laboratory expenses as well as costs for all
professionals participating in the provision of health
care.
The cost evaluation included only inpatient days pre-
ceding and following delivery in hospital units related to
pregnancy and GDM. The standard inpatient daily
charge of 30 Euros was added to the unit cost, which
was the cost to be paid by the patient. In the cost ana-
lysis, pre-delivery inpatient days were counted until the
delivery and during the immediate post-partum period
after delivery using the average national inpatient day
cost [23]. Delivery cost and inpatient day costs due to
delivery were counted separately using the Tampere Uni-
versity Hospital unit cost [24], which was used to obtain
detailed DRG (Diagnosis Related Groups) information.
Delivery unit costs included a standard number of in-
patient days, depending on the mode of delivery. In
addition, delivery-related operation costs included the
salary costs of obstetric staff, including administrative
expenses, medication and the cost of neonatal care in
cases without an ICD-diagnosis. The newborn babies’
hospital stays were calculated separately in cases when
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unit because of a disease involving organic complications
or another ICD-10 diagnosis.
If the newborn had an ICD-10 diagnosis code, the
costs of the newborn’s care were evaluated using the
classification of the delivery hospital, where the costs of
newborn babies were allocated to one of three possible
unit cost categories, depending on the newborns’ birth-
weight, ICD-10 diagnosis code and the number of in-
patient days in hospital. In the case of rooming-in, the
costs of the newborn baby’s care were included in the
mother’s delivery unit cost.
Medication costs included insulin costs but not the
costs of glucose monitoring at home, as these were known
to be minor [23]. Insulin costs were calculated for a period
of 2.5 months and included health insurance reimburse-
ments. According to the Finnish national guidelines, insu-
lin treatment should be started, if necessary, at the 30th
gestational week and should continue until delivery [25].
The costs of the oral glucose tolerance test (OGTT) as a
diagnostic test for GDM were assumed to have been in-
curred once in both groups. In the original study, a patho-
logic OGTT result at 8–12 weeks’ gestation was a
criterion for exclusion from the study, which meant that a
large amount of information concerning the costs of
OGTT was missed (N = 174).
Statistical analysis
The association between the groups and continuous
variables was tested with the Mann–Whitney U-test and
with the chi-square test for categorical variables. Costs
were reported as means and were rounded to whole
Euros. Mann–Whitney U-test was used to analyse the
differences between the two groups. Ratios or propor-
tions of prenatal complications and mode of delivery
variables were calculated using the chi-square test or, if
the assumptions of the chi-square tests were not valid,
Fisher's exact test. Total costs were adjusted for mater-
nal age, body mass index and education. These adjust-
ments were performed using ordinal regression analysis,
because cost distributions were not normally distributed.
The results were considered to be statistically significant
if p < 0.05. All analyses were performed using SPSS soft-
ware (version 19).
Results
From a total of 848 women with an elevated risk of GDM,
251 (29.6%) had a confirmed GDM diagnosis by the end
of the pregnancy, while 597 women (70.4%) formed a
comparison group (Table 1). At the beginning of preg-
nancy the mean age of the GDM group was 30.6 years,
and in the comparison group 29.2 years (p < 0.001).
Women with a GDM diagnosis were significantly more
overweight (28.8 vs. 24.9 kg/m²; p < 0.001), were morelikely to have been diagnosed with GDM in earlier preg-
nancies (p < 0.001) and had a greater number of previous
deliveries (p < 0.016). In contrast, there were no statistical
correlations between a GDM diagnosis and the level of
education or smoking habits. The sum of GDM risk fac-
tors was higher among women with GDM (1.51 vs. 0.92,
p < 0.001) than among women without GDM (Table 1).
There were no statistically significant differences between
groups in prevalence of diseases such as elevated blood
pressure, high blood cholesterol, diabetes, cardiovascular
diseases, cancer, rheumatoid arthritis, bronchitis, depres-
sion or back problems (not shown in table).
The adjusted mean total health care costs to the munici-
pality and the patient were 25.1% higher among women
diagnosed with GDM (€6,432 vs. €5,143, p < 0.001, Table 2).
In addition, the use of insulin as a way to measure the se-
verity of GDM was associated with higher total costs
(€7,026 vs. €5,766, p < 0.001). The mean cost of visits to a
public health nurse and to a doctor were slightly lower in
the GDM group (€1,008 vs. €1,048, p = 0.019). The mean
cost of visits to secondary care was 2.3 times higher for
women diagnosed with GDM (€676 vs. €291, p < 0.001).
Although the costs were minor, GDM was associated with
increased costs (€40 vs. €1, p < 0.001) resulting from visits
to a diabetes nurse, but there was no difference in the
mean costs of visits to a dietician (p = 0.79). Insulin therapy
was used by 29.1% of women diagnosed with GDM. The
medication costs during the 2.5 month calculation period
were €85, of which the proportion refunded by the Social
Insurance institution of Finland was 42% of the total cost
directly to the patient. The mean cost of total inpatient
days before and after delivery was 44% higher in the GDM
group (€491 vs. €341, p < 0.001) than in the comparison
group.
There were no statistical differences between the
groups in terms of delivery cost to the patient (€105 vs.
€101, p = 0.14). Also, the delivery cost to the municipal-
ity of residence was only slightly higher for women diag-
nosed with GDM than for women without GDM
(€2,144 vs. €2,048, p = 0.051, Table 3). GDM was asso-
ciated with a higher rate of labour induction (27.1% vs.
13.9%, p < 0.001, Table 4). The proportion of elective
and emergency caesarean sections was higher in the
GDM group (21.1% vs. 14.9%), whereas vaginal delivery
was more frequent in women without a GDM diagnosis
(78.9% vs. 85.1%, Table 4). As for the newborn baby, re-
suscitation was needed more often in the GDM group
(5 vs. 1, p < 0.010). There were no statistical correlations
between the groups in other prenatal complications or
health outcomes (Table 4).
Costs of outpatient visits both to primary and second-
ary care clinics were 28.6% higher, and inpatient service
costs were 44% higher among women with GDM than
among women without GDM (Table 5). The cost of
Table 1 Characteristics (mean ± SD or frequency and percentage) and distribution of risk factors of GDM of women
with and without GDM
Women with GDM Missing Comparison group† Missing p-value
*n = 251 n = 597
Age categories
−29 102 (40.6) 312 (52.3)
30-34 90 (35.9) 200 (33.5)
35+ 59 (23.5) 0 85 (14.2) 0 0.001
BMI categories
Normal (<25 kg/m²) 67 (27.0) 345 (57.8)
Overweight (25 to 29.9 kg/m²) 91 (36.7) 175 (29.4)
Obese (> = 30 kg/m²) 90 (36.3) 3 76 (12.8) 1 <0.001
Education level‡
Low 98 (40.5) 192 (33.4)
Medium 94 (38.8) 254 (44.3)
High 50 (20.7) 9 128 (22.3) 23 0.15
Previous deliveries 1.10 ± 1.18 0 0.89 ± 0.99 0 0.016
Smoking during pregnancy
No 225 (91.8) 556 (93.7)
Stopped during first trimester 6 (2.4) 11 (1.9)
Continued smoking after first trimester 14 (5.7) 6 26 (4.4) 4 0.60
Gestational diabetes in any earlier pregnancy 64 (28.3) 4 38 (7.3) 17 <0.001
Risk factors of GDM
BMI≥ 25 kg/m² 181 (73.3%) 4 247 (42.8%) 20 <0.001
Macrosomic children in earlier pregnancy 14 (5.7%) 4 12 (2.1%) 20 0.007
GDM in earlier pregnancy 64 (25.9%) 4 38 (6.6%) 20 <0.001
Diabetes in relatives 106 (42.9%) 4 227 (39.3%) 20 0.34
Age≥ 40 years 4 7 (1.2%) 20 0.099
Polycystic ovarian syndrome 0 4 1 (0,2%) 20 1.00
Sum of risk factors 1.51 (0.74) 4 0.92 (0.75) 20 <0.001
*Inclusion criteria (one or more): pathologic oral glucose tolerance test, initiated insulin treatment during pregnancy, diagnosed GDM.
†Without GDM diagnostic criteria.
‡Low = vocational school or less.
Medium = polytechnic level.
High = academic education.
Kolu et al. BMC Pregnancy and Childbirth 2012, 12:71 Page 4 of 7
http://www.biomedcentral.com/1471-2393/12/71delivery to the patient and the municipality was only
slightly (4.7%) higher among women diagnosed with
GDM, and was the largest single component of the
mean costs in both groups. GDM was associated with
49% higher costs for treatment in a neonatal intensive
care unit immediately after the birth than for the infants
of mothers without GDM.
Discussion
A confirmed GDM diagnosis was associated with a sig-
nificant increase in total health care costs. In addition to
increased costs to the patient and to the municipality of
residence, GDM was also associated with more frequent
elective and emergency caesarean sections, which, in
turn, is associated with an increased risk of adversematernal outcomes [26]. On the other hand, the greater
number of caesarean sections in the GDM group may
explain the small number of delivery complications, such
as bone fractures and shoulder dystocia occurring in the
GDM group.
Visits to primary health care providers were not corre-
lated with GDM, which is partly explained by the na-
tional guidelines concerning GDM. In Finland the
municipalities provide antenatal care services for all
pregnant women free of charge. Almost all pregnant
women (99.7%) utilize municipal maternity care services,
although there are also private services available [27],
which minimized the amount of missing information.
Women who are pregnant for the first time make a total
of 14–18 visits to a public health nurse or a doctor in an
Table 2 Use of health care services (mean and SD or frequency and percentage) and mean costs per person during
pregnancy and postnatal period
Number of units Mean cost, €*
Unit cost, € Women with Comparison Women with Comparison p-value
GDM (n = 251) group (n = 597) GDM (n = 251) group (n = 597)
Women
Visits to primary care 72 €/ visit 14.0 ± 3.3 14.6 ± 2.8 1,008 1,048 0.019
Visits to secondary care 208 €/ visit† 3.25 ± 2.9 1.40 +/− 1.6 676 291 <0.001
Visits to a diabetes nurse 91 €/ visit† 0.44 ± 0.86 0.01 ± 0.13 40 1 <0.001
Visits to a dietician 164 €/ visit† 0.01 ± 0.12 0.01 ± 0.14 2 2 0.79
OGTT 25 €/ test 25 25
Insulin therapy 85 € / 2.5 month 73 (29.1%) 0 (0.0%) 25 - <0.001
Hospital days before and after delivery 330 €/ day‡ 1.49 ± 2.70 1.03 ± 2.20 491 341 <0.001
Delivery cost to the patient 30 €/ day 3.51 ± 1.22 3.37 ± 1.14 105 101 0.14
Delivery cost to the municipality (Table 3) 2,144 2,048
Newborn
Cost of neonatal intensive care unit to
the patient§
30 €/ day 4.43 ± 1.57 4.41 ± 1.42 133 132 0.78
Cost of neonatal intensive care unit to
the municipality (Table 3)
1,783 1,154
Total mean costs, € 6,432 5,143
Unadjusted <0.001
Adjusted ∣∣ <0.001
*Costs are rounded to whole Euros.
†Including outpatient charge (27 € per visit).
‡ Including standard inpatient daily charge (30 € per day) and all costs to municipalities and patients.
§ Inpatient daily charge (30 € per day) during 1–7 hospital days.
∣∣Adjusted for maternal age, body mass index and education.
Table 3 Mean costs of delivery and treatment in a neonatal intensive care unit among women with risk of GDM
Women with GDM Comparison group
Unit cost, € Number of units Cost, € Number of units Cost, € p-value
Women n = 251 n = 597
Vaginal delivery 1,758 € 178 (70.9%) 312,924 458 (76.7%) 805,164
Instrumental delivery 2,477 € 20 (8.0%) 49,540 50 (8.4%) 123,850
Elective cesarean section 2,741 € 20 (8.0%) 54,820 35 (5.9%) 95,935
Emergency cesarean section 3,662 € 33 (13.1%) 120,846 54 (9.0%) 197,748 0.18
Mean delivery cost per person 2,144 2,048 0.051
Newborn* n = 118 n = 183
Neonatal intensive care unit †
Category A 8,107 €/ period 3 24,321 9 72,963
Category B 6,760 €/ period 5 33,800 0 -
Category C 3,541 €/ period 110 389,510 174 616,134
Mean newborn cost per person 1,783 1,154 p < 0.001
*Newborns without ICD-10 diagnosis were not included.
†Category A: Birthweight 1500–2499 g, inpatient days 1–22, including required examinations and treatments and ≤ 2 diseases with organic complications.
Category B: Birthweight >2500 g, inpatient days 1–11, including required examinations and treatments and ≥ 1 disease with organic complications.
Category C: Birthweight >2500 g, inpatient days 1–7, including required examinations and treatments. No disease with organic complications.
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Table 4 Mode of delivery and prenatal complications/
health outcomes
Women with
GDM
Comparison
group
p-value
n = 251 (%) n = 597 (%)
Women
Induction of labour 68 (27.1%) 83 (13.9%) <0.001
Mode of delivery
Vaginal delivery 198 (78.9%) 508 (85.1%)
Caesarean section 53 (21.1%) 89 (14.9%) 0.027
Newborn
Serious perinatal
complication
1 11
Death 0 (0.0%) 0 (0.0%) -
Shoulder dystocia 0 (0.0%) 3 (0.5%) 0.56
Bone fracture 1 (0.4%) 8 (1.3%) 0.22
Nerve palsy 0 (0.0%) 0 (0.0%) -
Respiratory care 4 (1.6%) 4 (0.7%) 0.20
Blood change 0 (0.0%) 0 (0.0%) -
Phototherapy 31 (12.4%) 56 (9.4%) 0.19
Resuscitation 5 (2.0%) 1 (0.2%) 0.010
Antibiotic treatment 25 (10.0%) 50 (8.4%) 0.46
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mended number of visits to antenatal care providers for
multiparous women is 10–14 [28]. However, GDM is
associated with increased outpatient costs due to visitsTable 5 Summary of allocation of mean costs to the
patient and municipality among women with and
without a GDM diagnosis and their newborn
Women with
GDM
Comparison
group
p-value
n = 251 n = 597
€ €
Women
Outpatient costs* 1,726 1,342 p <
0.001
Inpatient costs† 491 341 p <
0.001
Delivery costs‡ 2,249 2,149 p =
0.054
Other costs§ 50 25
Newborn
Neonatal intensive care unit
costs‡
1,916 1,286 p <
0.001
Total costs 6,432 5,143 p <
0.001
*Sum of costs associated to visits to primary and secondary care.
†Sum of costs associated to inpatient days before and after delivery.
‡Sum of cost to the patient and the municipality.
§ Cost of oral glucose tolerance test (25 €) + medication.to secondary care, which was almost three times higher
than the cost of a visit to a public health nurse or a doc-
tor working in primary health care.
According to earlier studies being overweight, espe-
cially as a GDM risk factor, imposes a considerable
and increasing burden on health services [11,12].
According to data from the Medical Birth Register for
2006 (N = 59,053), 34.2% of the women had at least
one GDM risk factor and, of these, 20.4% had a con-
firmed GDM diagnosis [10]. According to our earlier
study [10], the mean costs of primary health care vis-
its, including the costs of OGTTs, were 40.5% higher
among women with at least one GDM risk factor and
a GDM diagnosis than among women without any risk
factors or a GDM diagnosis. Even being moderately
overweight before pregnancy correlated with higher
hospitalisation costs [11]. In addition, total outpatient
and inpatient costs were three times higher among the
severely prepregnancy obese (BMI >35 kg/m²) than
among women of normal weight (BMI <25 kg/m²)
[11].
All participants in our study had a risk of GDM, which
may increase pre-and postnatal health care costs. We
have previously reported that the costs of visits to ante-
natal health care to see a doctor or a public health nurse
did not differ according to the woman’s confirmed GDM
status [10]. However, there were statistically significant
differences between the numbers of visits and the costs
of the group with neither GDM risk factors nor a GDM
diagnosis and the group with at least one GDM risk fac-
tor and a confirmed GDM diagnosis [10].
This study had a number of limitations. For example,
there was a risk of confounding which may reduce in-
ternal validity. However conditions such as elevated
blood pressure were evenly distributed among groups
which appears to offset this limitation. Another weak-
ness was that the cost evaluation of inpatient days was
based on inpatient days on wards related to pregnancy
and gestational diabetes care. The use of ICD-10 diagno-
sis codes as inclusion criteria would have been more re-
liable for quantifying relevant inpatient days. On the
other hand, GDM may increase the number of inpatient
days for various reasons, which was a reason for the use
of our current inclusion criteria. In addition, the study
may underestimate the inpatient and outpatient days oc-
curring after delivery, because readmissions were not
taken into consideration. The costs were taken into ac-
count until the last day the mother or baby spent in hos-
pital directly after birth, which was a precise cutpoint
for cost evaluation.
Another potential limitation concerned unit costs,
which were those of the Tampere University Hospital
[24] and average national unit costs [23]. Health care
costs were based on secondary care unit costs of one
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eration when interpreting the study findings. However,
the use of Tampere University Hospital unit costs pro-
vided an opportunity to evaluate secondary care costs in
detail as the data available on national average health
care costs did not include detailed delivery costs or costs
of surgery based on ICD-10 diagnosis codes. The unit
costs of the Tampere University Hospital [24] were simi-
lar to average national costs, partly because the Tampere
University Hospital is a part of the Pirkanmaa Hospital
District, which is the second biggest hospital district in
Finland. Our study included only health care costs asso-
ciated with GDM, but omitted economic costs such as
the cost of productivity loss, which is a further limita-
tion. Thus the total health care costs of gestational dia-
betes mellitus among high-risk women may have been
underestimated. Since the data was based on a rando-
mised intervention, the possibility that the intervention
had an effect on GDM incidence cannot be denied.
However, there were no differences between the trial
groups in GDM incidence [21] and thus the intervention
probably did not have an effect on the total cost of
GDM.Conclusion
The study findings emphasize the potential importance
of prevention programmes in saving money and improv-
ing the health of mothers and newborn babies. In further
studies, it would be useful to evaluate the cost-
effectiveness of health promotion programmes among
GDM patients.
Competing interests
The authors have no competing interests.
Authors’ contributions
PK wrote the manuscript and researched the data, JR performed the
statistical analysis. RL and PR reviewed and edited the manuscript and
contributed to the discussion. All authors have approved the final form of
the manuscript.
Acknowledgements
The article was funded by the Juho Vainio Foundation, the Yrjö Jahnsson
Foundation, medical research funding from Tampere University Hospital
(competitive research funding from the Pirkanmaa Hospital District), the
Academy of Finland, and the Ministry of Education and the Ministry of Social
Affairs and Health.
Author details
1UKK Institute for Health Promotion Research, Kaupinpuistonkatu 1, FI-33501,
Tampere, Finland. 2School of Health Sciences, University of Tampere,
Tampere, Finland.
Received: 16 December 2011 Accepted: 26 June 2012
Published: 24 July 2012
References
1. American Diabetes Association: Gestational diabetes mellitus. Diabetes
Care 2004, 27(Suppl 1):S88–90.2. Kieffer EC, Sinco B, Kim C: Health behaviors among women of
reproductive age with and without a history of gestational diabetes
mellitus. Diabetes Care 2006, 8:1788–1793.
3. Chu SY, Callaghan WM, Kim SY, Schmid CH, Lau J, England LJ, Dietz PM:
Maternal obesity and risk of gestational diabetes mellitus. Diabetes Care
2007, 8:2070–2076.
4. Teh WT, Teede HJ, Paul E, Harrison CL, Wallace EM, Allan C: Risk factors for
gestational diabetes mellitus: implications for the application of
screening guidelines. Aust N Z J Obstet Gynaecol 2011, 1:26–30.
doi:10.1111/j.1479-828X.2011.01292.x.
5. Bener A, Saleh NM, Al-Hamaq A: Prevalence of gestational diabetes and
associated maternal and neonatal complications in a fast-developing
community: global comparisons. Int J Womens Health 2011, 3:367–73.
6. Lamberg S, Raitanen J, Rissanen P, Luoto R: Prevalence and regional
differences of gestational diabetes mellitus and oral glucose tolerance
tests in Finland. Eur J Public Health 2012, 2:278–280.
7. Ferrara A: Increasing prevalence of gestational diabetes mellitus: a public
health perspective. Diabetes Care 2007, 30(Suppl. 2):S141–146.
8. Chen Y, Quick WW, Yang W, Zhang Y, Baldwin A, Moran J, Moore V, Sahai N,
Dall TM: Cost of gestational diabetes mellitus in the United States in
2007. Popul Health Manag 2009, 12:165–174.
9. Wier LM, Witt E, Burgess J, Elixhauser A: Hospitalizations related to
diabetes in pregnancy, 2008: statistical brief #102. In: Healthcare Cost
and Utilization Project (HCUP).HCUP Statistical Briefs. Rockville (MD).
Agency for Health Care Policy and Research (US) 2006, http://www.ncbi.nlm.
nih.gov/books/NBK52649/.
10. Kolu P, Raitanen J, Luoto R: Cost of gestational diabetes-related antenatal
visits in health care based on the Finnish Medical Birth Register. Prim
Care Diabetes 2011, 5:139–141.
11. Galtier-Dereure F, Montpeyroux F, Boulot P, Bringer J, Jaffiol C: Weight
excess before pregnancy: complications and cost. Int J Obes Relat Metab
Disord 1995, 19:443–448.
12. Galtier-Dereure F, Boegner C, Bringer J: Obesity and pregnancy:
complications and cost. Am J Clin Nutr 2000, 71(Suppl 5):1242S–1248S.
13. Casey BM, Lucas MJ, Mcintire DD, Leveno KJ: Pregnancy outcomes in
women with gestational diabetes compared with the general obstetric
population. Obstet Gynecol 1997, 90:869–873.
14. Schneider S, Hoeft B, Freerksen N, Fischer B, Roehrig S, Yamamoto S, Maul
H: Neonatal complications and risk factors among women with
gestational diabetes mellitus. Acta Obstet Gynecol Scand 2010,
16. 10.1111/j.1600-0412.2010.01040.x.
15. Ben-Haroush A, Yogev Y, Hod M: Epidemiology of gestational diabetes
mellitus and its association with Type 2 diabetes. Diabet Med 2004,
21:103–113.
16. Gregory KD, Kjos SL, Peters RK: Cost of non-insulin-dependent diabetes in
women with a history of gestational diabetes: implications for
prevention. Obstet Gynecol 1993, 81:782–786.
17. Davenport MH, Campbell MK, Mottola MF: Increased incidence of glucose
disorders during pregnancy is not explained by pre-pregnancy obesity
in London, Canada. BMC Pregnancy Childbirth 2010, 10:85.
18. Meltzer SJ, Snyder J, Penrod JR, Nudi M, Morin L: Gestational diabetes
mellitus screening and diagnosis: a prospective randomised controlled
trial comparing costs of one-step and two-step methods. BJOG 2010,
117:407–415.
19. Nicholson WK, Fleisher LA, Fox HE, Powe NR: Screening for gestational
diabetes mellitus: a decision and cost-effectiveness analysis of four
screening strategies. Diabetes Care 2005, 28:1482–1484.
20. Kim C, Herman WH, Vijan S: Efficacy and cost of postpartum screening
strategies for diabetes among women with histories of gestational
diabetes mellitus. Diabetes Care 2007, 30:1102–1106.
21. Luoto R, Kinnunen TI, Aittasalo A, Kolu P, Raitanen J, Ojala K, Mansikkamäki
K, Lamberg S, Vasankari T, Komulainen T, Tulokas S: Primary prevention of
gestational diabetes mellitus and large-for-gestational-age newborns by
lifestyle counseling –a cluster-randomized controlled trial. PLoS Medicine
2011, 8:e1001036.
22. Luoto RM, Kinnunen TIM, Aittasalo Ojala K, Mansikkamäki K, Toropainen E,
Kolu P, Vasankari T: Prevention of gestational diabetes: design of a
cluster-randomized controlled trial and one-year follow-up. BMC
Pregnancy Childbirth 2010, 10:39.
23. Hujanen T, Kapiainen S, Tuominen U, Pekurinen M: Terveydenhuollon
yksikkökustannukset Suomessa vuonna 2006 Health care unit costs in
